170 related articles for article (PubMed ID: 18523852)
1. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.
Cornetta T; Palma S; Aprile I; Padua L; Tonali P; Testa A; Cozzi R
Cell Biol Toxicol; 2009 Aug; 25(4):321-30. PubMed ID: 18523852
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage.
Prigione A; Begni B; Galbussera A; Beretta S; Brighina L; Garofalo R; Andreoni S; Piolti R; Ferrarese C
Neurobiol Dis; 2006 Jul; 23(1):36-43. PubMed ID: 16563783
[TBL] [Abstract][Full Text] [Related]
3. Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072
[TBL] [Abstract][Full Text] [Related]
4. Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the L-dopa.
Agil A; Durán R; Barrero F; Morales B; Araúzo M; Alba F; Miranda MT; Prieto I; Ramírez M; Vives F
J Neurol Sci; 2006 Jan; 240(1-2):31-6. PubMed ID: 16219327
[TBL] [Abstract][Full Text] [Related]
5. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.
Andreadou E; Nikolaou C; Gournaras F; Rentzos M; Boufidou F; Tsoutsou A; Zournas C; Zissimopoulos V; Vassilopoulos D
Clin Neurol Neurosurg; 2009 Nov; 111(9):724-8. PubMed ID: 19632030
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood markers of oxidative stress in Parkinson's disease.
Younes-Mhenni S; Frih-Ayed M; Kerkeni A; Bost M; Chazot G
Eur Neurol; 2007; 58(2):78-83. PubMed ID: 17565220
[TBL] [Abstract][Full Text] [Related]
7. The effects of levodopa on word intelligibility in Parkinson's disease.
De Letter M; Santens P; Van Borsel J
J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
[TBL] [Abstract][Full Text] [Related]
8. Superoxide dismutase activity in early and advanced Parkinson's disease.
Bostantjopoulou S; Kyriazis G; Katsarou Z; Kiosseoglou G; Kazis A; Mentenopoulos G
Funct Neurol; 1997; 12(2):63-8. PubMed ID: 9238339
[TBL] [Abstract][Full Text] [Related]
9. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment.
Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
Neurodegener Dis; 2011; 8(3):109-16. PubMed ID: 20714110
[TBL] [Abstract][Full Text] [Related]
11. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment.
Duran R; Barrero FJ; Morales B; Luna JD; Ramirez M; Vives F
Mov Disord; 2010 Mar; 25(4):489-93. PubMed ID: 20063406
[TBL] [Abstract][Full Text] [Related]
12. Recognition of category-related visual stimuli in Parkinson's disease: before and after pharmacological treatment.
Righi S; Viggiano MP; Paganini M; Ramat S; Marini P
Neuropsychologia; 2007 Oct; 45(13):2931-41. PubMed ID: 17662314
[TBL] [Abstract][Full Text] [Related]
13. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
14. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease.
Degirmenci B; Yaman M; Haktanir A; Albayrak R; Acar M; Caliskan G
Neurosci Lett; 2007 Apr; 416(3):294-8. PubMed ID: 17317000
[TBL] [Abstract][Full Text] [Related]
15. Plasma and urinary HPLC-ED determination of the ratio of 8-OHdG/2-dG in Parkinson's disease.
Bolner A; Pilleri M; De Riva V; Nordera GP
Clin Lab; 2011; 57(11-12):859-66. PubMed ID: 22239015
[TBL] [Abstract][Full Text] [Related]
16. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
Palmer SJ; Eigenraam L; Hoque T; McCaig RG; Troiano A; McKeown MJ
Neuroscience; 2009 Jan; 158(2):693-704. PubMed ID: 18722512
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease.
Prigione A; Piazza F; Brighina L; Begni B; Galbussera A; Difrancesco JC; Andreoni S; Piolti R; Ferrarese C
Neurosci Lett; 2010 Jun; 477(1):6-10. PubMed ID: 20399833
[TBL] [Abstract][Full Text] [Related]
18. Quantitative study of salivary secretion in Parkinson's disease.
Tumilasci OR; Cersósimo MG; Belforte JE; Micheli FE; Benarroch EE; Pazo JH
Mov Disord; 2006 May; 21(5):660-7. PubMed ID: 16419045
[TBL] [Abstract][Full Text] [Related]
19. Levodopa and executive performance in Parkinson's disease: a randomized study.
Pascual-Sedano B; Kulisevsky J; Barbanoj M; García-Sánchez C; Campolongo A; Gironell A; Pagonabarraga J; Gich I
J Int Neuropsychol Soc; 2008 Sep; 14(5):832-41. PubMed ID: 18764978
[TBL] [Abstract][Full Text] [Related]
20. Gait and balance disorders in Parkinson's disease: impaired active braking of the fall of centre of gravity.
Chastan N; Do MC; Bonneville F; Torny F; Bloch F; Westby GW; Dormont D; Agid Y; Welter ML
Mov Disord; 2009 Jan; 24(2):188-95. PubMed ID: 18973252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
